Increasing Patient Acceptance and Adherence Toward Insulin

Figures & data

Figure 1. Current and emerging basal insulins in the United States. Adapted from Refs. [21,22].

^aApproved by the US FDA since February 2015.^bApproved by the US FDA since September 2015.^cApproved by the US FDA since 18 December 2015.*Peglispro is no longer in development.

Figure 2. Current and emerging prandial insulins in the United States. Adapted from Ref. [22].

^aApproved by the US FDA since June 2014.^bNot currently approved by the US FDA.^cApproved by the US FDA in May 2015.

Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648–659.

 PubMed Web of Science ®Google Scholar

US FDA. Drugs@FDA; [cited 2016 Jan 12]. Available from: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA

 Google Scholar